What D7921 means

D7921 covers the collection and application of an autologous blood concentrate product. "D" is dental, "79" is this oral surgery (other surgical procedures) group, and "21" is this blood concentrate procedure. An autologous blood concentrate product is made from the patient's own blood ('autologous' = from the same person): a sample of the patient's blood is drawn (collected), and then processed — typically by centrifugation (spinning the blood to separate its components) — to concentrate the platelets and associated growth factors (and, in some preparations, to form a fibrin matrix). The resulting product is rich in platelets and growth factors — examples include PRP (platelet-rich plasma), PRF (platelet-rich fibrin), PRGF, and similar preparations. This concentrate is then applied at a surgical site (e.g., placed into an extraction socket, mixed with a bone graft, or applied at a surgical/implant site). The platelets and growth factors in the concentrate can promote and enhance healing and tissue regeneration (growth factors signal and stimulate the healing/regenerative processes). So D7921 is for collecting the patient's blood, processing it into a concentrate, and applying it to aid healing.

So it's making a healing-promoting concentrate from the patient's own blood (rich in platelets/growth factors) and applying it at a surgical site to enhance healing.

These autologous blood concentrates are used in oral surgery (and dentistry) to potentially improve outcomes — for example, in extraction sites (to aid socket healing and reduce complications like dry socket), with bone grafts/ridge preservation (to enhance the grafting), in sinus augmentation, around implants, and in other surgical/regenerative procedures. The appeal is that they're autologous (the patient's own blood — biocompatible, no foreign material, low risk) and they harness the body's own healing factors. D7921 covers the whole process (collection and application) as a procedure, typically done in addition to the primary surgical procedure it's aiding (the extraction, graft, etc., which has its own code). Note this is distinct from D7922 (placement of an intra-socket biological dressing for hemostasis/clot stabilization) — D7921 is specifically the autologous blood concentrate product. Coverage varies (these adjunctive regenerative procedures may have variable coverage); documentation of the procedure and its purpose supports the claim.

When it's typically used

D7921 is reported for collecting a sample of the patient's own blood, processing it into a concentrate rich in platelets and growth factors (e.g., PRP or PRF), and applying it at a surgical site to aid healing/regeneration. It's used adjunctively with procedures like extractions, bone grafts/ridge preservation, sinus augmentation, or implant placement, to enhance healing. It's distinct from D7922 (intra-socket biological dressing for hemostasis).

How much does D7921 cost?

The collection and application of an autologous blood concentrate is a moderate additional fee, often roughly 150 to 600+ USD depending on region and the preparation — for drawing the blood, processing it, and applying the concentrate (in addition to the primary procedure it's aiding, which has its own fee). The cost reflects the materials/equipment (centrifuge, kits) and the procedure. Coverage varies (often considered adjunctive). Verify your specific coverage.

Is D7921 covered by insurance?

Coverage varies — autologous blood concentrate is an adjunctive regenerative procedure, and not all plans cover it (some consider it elective/not a covered benefit, while others may cover it in certain contexts). Documentation of the procedure (the collection and application of the concentrate) and its purpose (aiding healing at the surgical site) supports the claim. It's reported in addition to the primary procedure it's aiding. It's distinct from D7922 (intra-socket biological dressing for hemostasis). Verifying coverage is important.

What an autologous blood concentrate is

An autologous blood concentrate is made from the patient's own blood, and understanding it clarifies the code.

Understanding what an autologous blood concentrate is clarifies D7921. Blood contains various components — red cells, white cells, platelets, and plasma (with proteins including clotting/growth factors). Platelets are especially important for healing: they're involved in clotting, and they release growth factors (signaling proteins) that stimulate healing and tissue regeneration (recruiting cells, promoting new tissue/blood vessel formation, etc.). An autologous blood concentrate is a product made by taking the patient's own blood ('autologous') and processing it to concentrate these beneficial components — typically: collection — drawing a sample of the patient's blood (like a routine blood draw); and processing — spinning the blood in a centrifuge to separate its components, isolating and concentrating the platelet-rich portion (and, in some preparations, forming a fibrin clot/matrix that holds the platelets and growth factors). The result is a concentrate rich in platelets and growth factors.

Different preparations exist, including: PRP (platelet-rich plasma) — a liquid concentrate of platelets in plasma; PRF (platelet-rich fibrin) — a fibrin matrix (a clot-like gel) rich in platelets and growth factors (a 'second-generation' preparation, often used as a membrane or plug); and others (PRGF, CGF, etc.). These differ in the processing and form, but share the concept of an autologous, platelet/growth-factor-rich product. So an autologous blood concentrate is a healing-promoting product made by concentrating the patient's own platelets and growth factors. It's prepared from the patient's blood at the time of the procedure. For patients, understanding what an autologous blood concentrate is — a concentrate of the patient's own platelets and growth factors — clarifies the code. It concentrates healing factors from the patient's blood. It's prepared at the procedure. Understanding this helps patients see that an autologous blood concentrate is a product made from the patient's own blood — by drawing a sample and processing it (typically centrifuging it to separate and concentrate the platelet-rich portion, and in some preparations forming a fibrin matrix) to produce a concentrate rich in platelets and the growth factors they release (which stimulate healing and tissue regeneration) — with preparations including PRP (platelet-rich plasma), PRF (platelet-rich fibrin, a fibrin matrix), and others, all sharing the concept of an autologous, platelet/growth-factor-rich product prepared from the patient's blood at the time of the procedure.

How it aids healing

The concentrate's growth factors aid healing, and understanding this clarifies its purpose.

The way an autologous blood concentrate aids healing clarifies its purpose. The key is the concentrated platelets and growth factors: platelets — when activated, platelets release a host of growth factors (such as PDGF, TGF-β, VEGF, and others) — these are signaling molecules that orchestrate healing; growth factors' effects — they stimulate processes important for healing and regeneration: recruiting and activating cells (e.g., cells that form new tissue and bone), promoting the formation of new blood vessels (angiogenesis — important for supplying a healing/grafted area), stimulating cell proliferation, and supporting tissue regeneration; and the fibrin matrix (in PRF and similar) — provides a scaffold that holds the platelets/growth factors at the site (releasing them over time) and supports cells and healing. So by delivering a concentrated dose of these healing factors (and, for PRF, a supportive matrix) to the surgical site, the concentrate aims to enhance and accelerate the healing/regeneration there.

Practical aims include: faster/better soft tissue healing (e.g., of an extraction socket or surgical wound), enhanced bone formation/grafting (supporting a bone graft or socket preservation), reduced complications (e.g., potentially reducing dry socket after extractions), and better outcomes in regenerative procedures (grafts, sinus augmentation, around implants). The evidence and degree of benefit can vary by application (these are used based on the rationale of harnessing the body's healing factors). So the concentrate aids healing by delivering the patient's own healing factors to the site. The surgeon applies it for this purpose. For patients, understanding how it aids healing — via concentrated growth factors — clarifies its purpose. It delivers healing factors to the site. The surgeon applies it. Understanding this helps patients see that an autologous blood concentrate aids healing through its concentrated platelets and growth factors — the platelets releasing growth factors (signaling molecules like PDGF, TGF-β, VEGF) that orchestrate healing by recruiting and activating cells, promoting new blood vessel formation, stimulating cell proliferation, and supporting tissue/bone regeneration, and (in PRF and similar) a fibrin matrix providing a scaffold that holds and releases these factors at the site — so by delivering a concentrated dose of the patient's own healing factors to the surgical site, it aims to enhance and accelerate healing (faster soft tissue healing, enhanced bone formation/grafting, potentially reduced complications like dry socket, and better regenerative outcomes), with the degree of benefit varying by application.

Where it's used in oral surgery

Autologous blood concentrates have various uses, and understanding them clarifies the applications.

Autologous blood concentrates are used in various oral surgery and dental applications — and understanding them clarifies where D7921 applies. Common applications: extraction sites — placing the concentrate (e.g., a PRF plug) into an extraction socket to aid socket healing and potentially reduce complications (like dry socket / alveolar osteitis), and support socket preservation; bone grafts / ridge preservation — mixing the concentrate with bone graft material (or applying it with the graft) to enhance the grafting (supporting bone formation), e.g., in ridge preservation after extraction or ridge augmentation; sinus augmentation — using it with sinus lift/augmentation procedures (to support the grafting and healing); implant sites — applying it around implants (at placement) to potentially enhance healing/integration; periodontal/regenerative procedures — in some periodontal regenerative procedures; and soft tissue healing — to aid soft tissue healing in various surgical sites. So the concentrate is used adjunctively across many procedures where enhanced healing/regeneration is desired.

In each case, D7921 (the collection and application of the concentrate) is done in addition to the primary procedure it's aiding (the extraction, graft, sinus augmentation, implant, etc., which has its own code) — the concentrate is an adjunct that supports that procedure's healing. The decision to use it is based on the case and the provider's approach (some providers use these routinely for certain procedures; others selectively). So autologous blood concentrates are used adjunctively in many procedures to support healing. The surgeon applies them where beneficial. For patients, understanding where they're used clarifies the applications. They're used to support healing in many procedures. The surgeon applies them adjunctively. Understanding this helps patients see that autologous blood concentrates are used in various oral surgery/dental applications — in extraction sites (aiding socket healing and potentially reducing complications like dry socket), with bone grafts/ridge preservation (enhancing the grafting and bone formation), in sinus augmentation, around implants (potentially enhancing healing/integration), in periodontal/regenerative procedures, and for soft tissue healing — always adjunctively (D7921, the collection and application, done in addition to the primary procedure it's aiding, which has its own code), with the decision to use it based on the case and the provider's approach, to support enhanced healing/regeneration where desired.

Autologous concentrate vs the socket dressing code

D7921 differs from D7922, and understanding this clarifies the coding.

D7921 (autologous blood concentrate) is distinct from the related code D7922 (intra-socket biological dressing) — and understanding the difference clarifies the coding. The two codes: D7921 — collection and application of an autologous blood concentrate product (collecting the patient's blood, processing it into a platelet/growth-factor concentrate, and applying it — for aiding healing/regeneration — this code); D7922 — placement of an intra-socket biological dressing to aid in hemostasis or clot stabilization (per site/tooth) — placing a dressing/material into a socket specifically to help control bleeding (hemostasis) or stabilize the blood clot (e.g., for patients with bleeding concerns/clotting disorders or on blood thinners, or when standard measures are insufficient). So the codes differ in purpose and material: D7921 is the autologous blood concentrate (the patient's processed blood, for healing/regeneration); D7922 is an intra-socket dressing (for hemostasis/clot stabilization).

While both can involve placing something into a socket, their primary purposes differ — D7921's concentrate is about enhancing healing/regeneration (via growth factors), whereas D7922's dressing is about controlling bleeding/stabilizing the clot. The surgeon codes based on what's done and why: an autologous blood concentrate (from the patient's processed blood) applied for healing → D7921; a biological dressing placed in a socket for hemostasis/clot stabilization → D7922. The materials and intent distinguish them. So D7921 is specifically the autologous blood concentrate (for healing), distinct from the socket dressing for hemostasis (D7922). The surgeon codes appropriately. For patients, understanding that D7921 differs from D7922 clarifies the coding. They have different purposes. The surgeon codes by what's done. Understanding this helps patients see that D7921 (collection and application of an autologous blood concentrate — the patient's processed blood, rich in platelets/growth factors, applied to enhance healing/regeneration) is distinct from D7922 (placement of an intra-socket biological dressing to aid in hemostasis or clot stabilization — a dressing placed in a socket specifically to control bleeding or stabilize the clot, e.g., for bleeding concerns) — so although both can involve placing something in a socket, their purposes and materials differ (healing/regeneration via a blood concentrate vs hemostasis/clot stabilization via a dressing), and the surgeon codes based on what's done and why.

Frequently asked questions

What is the D7921 dental code?

It's the collection and application of an autologous blood concentrate product — drawing a sample of the patient's own blood, processing it (e.g., by centrifugation) into a concentrate rich in platelets and growth factors (like PRP or PRF), and applying it at a surgical site to aid healing/regeneration. 'Autologous' means it's the patient's own blood.

What is an autologous blood concentrate (like PRP or PRF)?

A product made from the patient's own blood — by drawing a sample and centrifuging it to concentrate the platelets and growth factors (and, in PRF, form a fibrin matrix). PRP (platelet-rich plasma) is a liquid concentrate; PRF (platelet-rich fibrin) is a fibrin matrix/gel. Both deliver concentrated healing factors from the patient's own blood.

How does it help?

The concentrated platelets release growth factors (signaling molecules) that stimulate healing and regeneration — recruiting cells, promoting new blood vessel formation, and supporting tissue/bone formation. Applied at a surgical site, it aims to enhance and accelerate healing (e.g., faster socket healing, enhanced grafting, potentially fewer complications like dry socket).

Where is it used?

Adjunctively in many procedures — in extraction sites (aiding socket healing, potentially reducing dry socket), with bone grafts/ridge preservation, in sinus augmentation, around implants, and in regenerative/soft tissue procedures. It's done in addition to the primary procedure it's aiding (which has its own code), to support enhanced healing.

Is it safe?

It's autologous (made from the patient's own blood), so it's biocompatible with no foreign material and a low risk of reactions or disease transmission — one of its appeals. It involves a blood draw and processing. As with any procedure, the provider discusses the specifics. The degree of benefit can vary by application.

Is it covered, and how is it different from D7922?

Coverage varies — it's an adjunctive regenerative procedure, and not all plans cover it. It's distinct from D7922 (an intra-socket biological dressing for hemostasis/clot stabilization — for controlling bleeding) — D7921 is the autologous blood concentrate for healing/regeneration. Verify your specific coverage.

This page is an independent, plain-language explanation for general information only. It is not billing, coding, or clinical advice. For the official CDT descriptor and current-year wording, refer to the American Dental Association.